TMP-SMX use in pregnancy is shaped by two specific concerns. Trimethoprim is a folate antagonist, and first-trimester exposure has been associated with neural tube and other defects in some studies. Sulfamethoxazole near term carries a theoretical risk of kernicterus (bilirubin displacement) in the newborn. Decisions are case-by-case and made with obstetric input.

Educational reference — not medical advice. This page describes what is generally known about a drug family. It cannot account for your history, your other medicines, or your circumstances. Decisions about your own treatment belong with your doctor or pharmacist.

The first-trimester concern

Trimethoprim — the second component of sulfamethoxazole/trimethoprim — inhibits dihydrofolate reductase. That is the same enzyme inhibited (more potently) by methotrexate and pyrimethamine. Folate is critical to the closure of the neural tube in the first weeks of pregnancy. Inhibiting folate metabolism around that window has been a theoretical concern for decades, and observational studies have produced signals — though not perfectly consistent ones — for an association between first-trimester TMP-SMX exposure and neural tube defects, cardiovascular defects, and oral clefts.

The absolute increase in risk in published data is modest. Many women with first-trimester TMP-SMX exposure have uncomplicated pregnancies. Folic acid supplementation, recommended for all reproductive-age women considering pregnancy, is particularly relevant in this context.

In current obstetric practice, TMP-SMX is generally avoided in the first trimester unless no suitable alternative exists. The decision considers the indication: an unequivocal need (e.g. Pneumocystis jirovecii pneumonia in an immunocompromised pregnant patient) tilts toward use; a more flexible indication (uncomplicated UTI, where alternatives such as nitrofurantoin or fosfomycin are available) tilts toward an alternative.

The late-pregnancy concern

Sulfamethoxazole and other sulfa antibiotics displace bilirubin from albumin-binding sites. In adults this rarely matters. In the newborn — especially the preterm or low-birthweight newborn, with immature liver bilirubin handling — displacement can raise unconjugated bilirubin, and very high unconjugated bilirubin can cross into the brain and cause kernicterus, a permanent neurological injury.

That mechanism is real, and it was demonstrated in the 1950s — but in a trial that gave sulfisoxazole directly to premature newborns, not to pregnant women. The distinction matters, and it is routinely lost. Kernicterus following exposure in the womb alone has never been reported. A review of 94 infants exposed in utero to sulfadiazine found no increase in prematurity, hyperbilirubinaemia, or kernicterus.

The largest test of the question is a Danish study covering 841,900 births, which looked at neonates exposed to a sulfonamide within four weeks of delivery. The crude figures showed an apparent doubling of neonatal jaundice — but once the analysis adjusted for gestational age, the association vanished entirely (odds ratio 1.03). The apparent signal was the maternal urinary infection causing preterm birth, and preterm birth causing the jaundice. The drug was not doing it.

What follows from this is narrower than the traditional teaching. Caution around a newborn who is preterm, jaundiced, or unwell remains sensible, because that is the setting the original evidence came from. Blanket avoidance of sulfa antibiotics in the third trimester does not follow from the data, and is not what current obstetric guidance advises. It is also worth being honest about the limits: no study has been large enough to rule out a rare effect, so "no evidence of harm" is not quite the same as "evidence of no harm."

What ACOG actually recommends

It is worth stating the guideline position directly, because it is more permissive than most patient-facing summaries imply. The American College of Obstetricians and Gynecologists holds that the evidence linking sulfonamides and nitrofurantoins to birth defects is mixed, and that:

During the second and third trimesters, sulfonamides and nitrofurantoins may continue to be used as first-line agents. In the first trimester, prescribing them is still considered appropriate when no other suitable alternative is available. And, pointedly: pregnant women should not be denied appropriate treatment for infections, because untreated infection carries its own serious maternal and fetal risks.

That last clause is the one most often dropped, and it changes the calculus. The question is never "is this drug risk-free" but "is this drug safer than the untreated infection." For pyelonephritis in pregnancy, the answer is not close.

A confounder that shapes the whole literature. Studies comparing treated women against untreated women systematically overstate the drug's effect, because the reason for treatment is itself a risk factor. Periconceptional urinary tract infection has been associated with nine separate birth defects — including hypoplastic left heart and cleft lip, the very defects attributed to the antibiotics used to treat it. The better studies use an active comparator, such as another antibiotic class, rather than no treatment. Those studies have generally been closer to null.

Two further points of proportion. A large multi-plan study of 1.2 million live births found no significant elevation in cardiovascular defects, cleft lip or palate, clubfoot, or urinary defects after first-trimester exposure when compared against penicillin- or cephalosporin-treated pregnancies. And where a positive association has been reported, the absolute effect is small — on the order of a handful of additional malformations per thousand pregnancies. Meta-analysis of this literature rates its own evidence quality as very low, with detectable publication bias.

Mid-pregnancy

The middle of pregnancy carries less of either specific concern than the first trimester (organogenesis) or the last weeks (kernicterus). TMP-SMX is sometimes used in this window when needed, with attention to the indication and to alternatives. Decisions are made by the obstetric team with the prescriber.

Sulfasalazine and other sulfa-family drugs

Sulfasalazine has been used in pregnancy in patients with active inflammatory bowel disease or rheumatologic disease where treatment is needed. Folate supplementation is typically given because of the folate-antagonist effect of the drug. The decision is made in conjunction with the gastroenterologist or rheumatologist and the obstetrician.

The non-antibiotic sulfonamides — furosemide, HCTZ, celecoxib, sulfonylureas, acetazolamide — each have their own pregnancy considerations independent of the sulfa label. Most are not first-line in pregnancy: thiazides are sometimes used for chronic hypertension (with caveats); loop diuretics are reserved for specific indications; sulfonylureas are not first-line in gestational diabetes (insulin and metformin are typically preferred); celecoxib and other NSAIDs are generally avoided in the third trimester (premature ductus arteriosus closure, oligohydramnios). These decisions belong to the obstetric and prescribing teams.

Allergy in pregnancy

A sulfa allergy label in pregnancy is treated as it would be outside pregnancy — most labels refer to past sulfa antibiotic reactions. The relevance is to the choice of antibiotic when an infection arises (UTI, MRSA infection). Many pregnancy-friendly alternatives exist for these indications, so a sulfa allergy is rarely a decisive constraint.

Pregnancy decisions belong to the obstetric team. Nothing on this page replaces the judgement of a clinician familiar with the specific pregnancy. The points above are general; the decision in a particular case considers gestational age, indication, alternatives, and patient-specific factors.

Breastfeeding

Sulfa antibiotics pass into breast milk in small amounts. For healthy term newborns, short courses of TMP-SMX in lactating mothers are usually considered acceptable. Breastfeeding a preterm or jaundiced newborn while on a sulfa antibiotic raises the same kernicterus concern that applies to late pregnancy, and is generally avoided. The decision belongs to the prescriber.

Folic acid

For all women planning pregnancy, daily folic acid supplementation is widely recommended (400 micrograms in most guidelines for low-risk pregnancies, higher in some specific situations). The recommendation is independent of any antibiotic exposure. Adequate folate stores reduce the baseline risk of neural tube defects regardless of medications used.

Sulfa during pregnancy.